- Investing.com
Metrics to compare | QNRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipQNRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.5x | −2.6x | −0.3x | |
PEG Ratio | −0.01 | −0.14 | 0.00 | |
Price/Book | 1.0x | 3.3x | 2.6x | |
Price / LTM Sales | - | 66.9x | 2.9x | |
Upside (Analyst Target) | 273.8% | 232.9% | 57.8% | |
Fair Value Upside | Unlock | 16.3% | 9.5% | Unlock |
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company’s lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases. It has a research agreement with Queensland University of Technology. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.